0001213900-15-004734.txt : 20150625 0001213900-15-004734.hdr.sgml : 20150625 20150625095101 ACCESSION NUMBER: 0001213900-15-004734 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150623 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20150625 DATE AS OF CHANGE: 20150625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TIANYIN PHARMACEUTICAL CO., INC. CENTRAL INDEX KEY: 0001362718 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204857782 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34189 FILM NUMBER: 15950798 BUSINESS ADDRESS: STREET 1: 23RD FLOOR, UNIONSUN YANGKUO PLAZA STREET 2: NO.2, BLOCK 3, RENMIN ROAD SOUTH CITY: CHENGDU, P.R. STATE: F4 ZIP: 610041 BUSINESS PHONE: 0086-028-86154737 MAIL ADDRESS: STREET 1: 23RD FLOOR, UNIONSUN YANGKUO PLAZA STREET 2: NO.2, BLOCK 3, RENMIN ROAD SOUTH CITY: CHENGDU, P.R. STATE: F4 ZIP: 610041 FORMER COMPANY: FORMER CONFORMED NAME: VISCORP, INC. DATE OF NAME CHANGE: 20060515 8-K 1 f8k062315_tianyinpharma.htm CURRENT REPORT

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT FOR ISSUERS SUBJECT TO THE

1934 ACT REPORTING REQUIREMENTS

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

 

June 23, 2015

Date of Report

(Date of Earliest Event Reported)

 

Tianyin Pharmaceutical Co., Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   000-52236   20-4857782
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 
23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3

South Renmin Road

Chengdu, P. R. China, 610041

(Address of principal executive offices (zip code))

 

+011-86-28- 8551-6696

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

 

 

 

 
 

 

Section 5-Corporate Governance and Management

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

On June 23, 2015, Tianyin Pharmaceutical Co., Inc. (the “Company”) held an annual shareholder meeting for the fiscal year ended June 30, 2014 (the “Annual Meeting”) in its office located in Chengdu, China. The Annual Meeting was originally scheduled to be held on May 25, 2015, but due to an insufficient amount of shares of the Company’s stock entitled to vote on such date, the Company was unable to achieve a quorum and therefore had to adjourn the meeting to June 23, 2015 (the “Adjourned Meeting”). At the Adjourned Meeting, a total of 13,775,888 shares were voted in person or by proxy, representing 46.55% of the 29,596,276 shares entitled to be voted as of the record date of March 30, 2015. According to our By-laws, as amended, when a quorum shall fail to attend any meeting of the stockholders, the Board of Directors may resolve that the adjourned meeting shall be held with the holders of more than one-third (1/3) of all the shares of the stock entitled to vote at the meeting, the presence of who shall constitute a quorum, and all matters shall be determined by a majority of the votes cast as at such meeting. Accordingly, the shares voted at the Adjourned Meeting constituted quorum.

 

All of our directors, specifically, Dr. Guoqing Jiang, Professor Jianping Hou, Professor Zunjian Zhang and Mr. Yong Zhan were re-elected at the Adjourned Meeting, with the votes casted as follows:

 

   Guoqing Jiang   Jianping Hou   Zunjian Zhang   Yong Zhan 
For   11,845,395    11,144,437    11,144,437    11,947,995 
Against   729,706    729,706    729,706    729,706 
Abstain   1,200,787    1,901,745    1,901,745    1,098,187 

  

Furthermore, the re-appointment of Paritz & Company, P.A. as our independent accountants to audit our financial statements as of June 30, 2015 and for the fiscal year then ending was approved and ratified, with 12,014,726 shares voted for, 1,759,829 shares voted against and 1,333 shares abstained for the proposal.

 

2
 

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TIANYIN PHARMACEUTICAL CO., INC.

 

By: /s/ Dr. Guoqing Jiang  
  Name:  Dr. Guoqing Jiang  
  Title:   Chief Executive Officer  

  

Dated:  June 25, 2015

 

3